|
||||||||||||||||||||
 |
||||||||||||||||||||
 |
||||||||||||||||||||
 April 2012Brickell enters into license agreement with Argyle Therapeutics, Inc. for exclusive rights to SIG990 (BBI-990), a novel compound with anti-inflammatory properties, for the treatment of rosacea and other dermatological indications.
Focused on the development of novel therapies for the treatment of skin and ocular surface diseases. Brickell Biotech, Inc. is a development-stage pharmaceutical company focused on the development of innovative, first-in class therapeutics to satisfy current unmet human needs in the global dermatology and ophthalmology markets.
|
||||||||||||||||||||
Brickell Biotech, Inc. © 2012 All Rights Reserved.
|
||||||||||||||||||||
